FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079883389> ?p ?o ?g. }

• W2079883389 endingPage "3065" @default.
• W2079883389 startingPage "3062" @default.
• W2079883389 abstract "Telmisartan is a unique angiotensin II receptor blocker (ARB) with the longest acting [ [1] Burnier M. Angiotensin II, type 1 receptor blockers. Circulation. 2001; 103: 904-912 Crossref PubMed Scopus (418) Google Scholar ], the strongest binding affinity to the receptor [ [2] Kakuta H. Sudoh K. Sasamata M. Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005; 25: 41-46 PubMed Google Scholar ], and selective peroxisome proliferation-activated receptor-gamma-modulating activity [ [3] Benson S.C. Pershadsingh H.A. Ho C.I. et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004; 43: 993-1002 Crossref PubMed Scopus (1033) Google Scholar ]. A recent meta-analysis by Xi et al. [ [4] Xi G.L. Cheng J.W. Lu G.C. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. Am J Hypertens. 2008; 21: 546-552 Crossref PubMed Scopus (24) Google Scholar ] of head-to-head randomized controlled trials (HRCTs) reveals that telmisartan monotherapy provides superior control of BP when compared with losartan monotherapy. Further, another meta-analysis by Zheng et al. [ [5] Zheng Z. Lin S. Shi H. A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension. J Clin Hypertens (Greenwich). 2010; 12: 414-421 Crossref PubMed Scopus (16) Google Scholar ] of HRCTs suggest that telmisartan's blood pressure (BP)-lowering capabilities are comparable to those of valsartan in monotherapy, but that telmisartan is more effective than valsartan when combined with hydrochlorothiazide (HCTZ). When BP targets are not reached with monotherapy, the combination of a diuretic with an ARB is a rational treatment option, as these therapies have complementary mechanisms of action [ [6] Meredith P.A. Angiotensin II, receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. Am J Cardiovasc Drugs. 2005; 5: 171-183 Crossref PubMed Scopus (38) Google Scholar ]. Moreover, single-pill fixed-dose combination (SFC) of an ARB and low-dose HCTZ provide a convenient and effective treatment option for patients who do not achieve blood pressure targets on monotherapy, without compromising the placebo-like tolerability of ARBs [ [6] Meredith P.A. Angiotensin II, receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. Am J Cardiovasc Drugs. 2005; 5: 171-183 Crossref PubMed Scopus (38) Google Scholar ]. Although a number of HRCTs of telmisartan plus HCTZ (telmisartan/HCTZ) versus other ARB/HCTZ have been published to date, there has been no meta-analysis of them except for the meta-analysis by Zheng et al. [ [4] Xi G.L. Cheng J.W. Lu G.C. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. Am J Hypertens. 2008; 21: 546-552 Crossref PubMed Scopus (24) Google Scholar ] to the best of our knowledge and belief. The sole meta-analysis [ [4] Xi G.L. Cheng J.W. Lu G.C. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. Am J Hypertens. 2008; 21: 546-552 Crossref PubMed Scopus (24) Google Scholar ], however, included only 2 HRCTs of telmisartan/HCTZ versus valsartan/HCTZ. Thus, the appropriate role of telmisartan/HCTZ in comparison with other ARB/HCTZ therapy on BP in the hypertensive population remains unclear. We performed the first meta-analysis of HRCTs of telmisartan/HCTZ versus other ARB/HCTZ therapy for reduction of BP in hypertension." @default.
• W2079883389 created "2016-06-24" @default.
• W2079883389 creator A5006435222 @default.
• W2079883389 creator A5050498443 @default.
• W2079883389 creator A5051671230 @default.
• W2079883389 creator A5068732831 @default.
• W2079883389 date "2013-09-01" @default.
• W2079883389 modified "2023-09-26" @default.
• W2079883389 title "A meta-analysis of randomized head-to-head trials of telmisartan versus other angiotensin II receptor blocker in combination with hydrochlorothiazide for reduction of blood pressure" @default.
• W2079883389 cites W1987395490 @default.
• W2079883389 cites W1995541915 @default.
• W2079883389 cites W2011522985 @default.
• W2079883389 cites W2026889191 @default.
• W2079883389 cites W2030812441 @default.
• W2079883389 cites W2031113601 @default.
• W2079883389 cites W2047867745 @default.
• W2079883389 cites W2048927121 @default.
• W2079883389 cites W2076929400 @default.
• W2079883389 cites W2092339133 @default.
• W2079883389 cites W2129697991 @default.
• W2079883389 cites W2147122080 @default.
• W2079883389 cites W2159729565 @default.
• W2079883389 cites W24673211 @default.
• W2079883389 doi "https://doi.org/10.1016/j.ijcard.2012.11.081" @default.
• W2079883389 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23200265" @default.
• W2079883389 hasPublicationYear "2013" @default.
• W2079883389 type Work @default.
• W2079883389 sameAs 2079883389 @default.
• W2079883389 citedByCount "4" @default.
• W2079883389 countsByYear W20798833892013 @default.
• W2079883389 countsByYear W20798833892014 @default.
• W2079883389 countsByYear W20798833892016 @default.
• W2079883389 crossrefType "journal-article" @default.
• W2079883389 hasAuthorship W2079883389A5006435222 @default.
• W2079883389 hasAuthorship W2079883389A5050498443 @default.
• W2079883389 hasAuthorship W2079883389A5051671230 @default.
• W2079883389 hasAuthorship W2079883389A5068732831 @default.
• W2079883389 hasConcept C104849204 @default.
• W2079883389 hasConcept C123915805 @default.
• W2079883389 hasConcept C126322002 @default.
• W2079883389 hasConcept C134018914 @default.
• W2079883389 hasConcept C2777387769 @default.
• W2079883389 hasConcept C2779716603 @default.
• W2079883389 hasConcept C2780288358 @default.
• W2079883389 hasConcept C2908929049 @default.
• W2079883389 hasConcept C71924100 @default.
• W2079883389 hasConcept C84393581 @default.
• W2079883389 hasConcept C98274493 @default.
• W2079883389 hasConceptScore W2079883389C104849204 @default.
• W2079883389 hasConceptScore W2079883389C123915805 @default.
• W2079883389 hasConceptScore W2079883389C126322002 @default.
• W2079883389 hasConceptScore W2079883389C134018914 @default.
• W2079883389 hasConceptScore W2079883389C2777387769 @default.
• W2079883389 hasConceptScore W2079883389C2779716603 @default.
• W2079883389 hasConceptScore W2079883389C2780288358 @default.
• W2079883389 hasConceptScore W2079883389C2908929049 @default.
• W2079883389 hasConceptScore W2079883389C71924100 @default.
• W2079883389 hasConceptScore W2079883389C84393581 @default.
• W2079883389 hasConceptScore W2079883389C98274493 @default.
• W2079883389 hasIssue "6" @default.
• W2079883389 hasLocation W20798833891 @default.
• W2079883389 hasLocation W20798833892 @default.
• W2079883389 hasOpenAccess W2079883389 @default.
• W2079883389 hasPrimaryLocation W20798833891 @default.
• W2079883389 hasRelatedWork W137606157 @default.
• W2079883389 hasRelatedWork W157621134 @default.
• W2079883389 hasRelatedWork W1991106890 @default.
• W2079883389 hasRelatedWork W2006698999 @default.
• W2079883389 hasRelatedWork W2097957153 @default.
• W2079883389 hasRelatedWork W2111190158 @default.
• W2079883389 hasRelatedWork W3149326891 @default.
• W2079883389 hasRelatedWork W3193972101 @default.
• W2079883389 hasRelatedWork W330879772 @default.
• W2079883389 hasRelatedWork W48752276 @default.
• W2079883389 hasVolume "167" @default.
• W2079883389 isParatext "false" @default.
• W2079883389 isRetracted "false" @default.
• W2079883389 magId "2079883389" @default.
• W2079883389 workType "article" @default.